慢性肾脏病-矿物质骨异常中硬骨抑素:阻断前需三思
本综述总结硬骨抑素在慢性肾脏病-矿物质骨异常(CKD-MBD)中的潜在作用,指出硬骨抑素单抗(如romosozumab)虽可治疗骨质疏松,但在CKD-MBD中可能干扰甲状旁腺功能亢进、肾性骨营养不良和血管钙化的多重交互,临床后果尚不明确,需建立有效风险获益比前解决关键研究目标。
要点
- 硬骨抑素主要由骨细胞产生,是骨形成和矿化的强效抑制剂。
- 硬骨抑素单抗在CKD-MBD中可能影响甲状旁腺功能亢进、肾性骨营养不良和血管钙化。
- 在CKD患者中建立硬骨抑素阻断的风险获益比前需解决关键研究目标。
核心结论
- 硬骨抑素阻断在CKD-MBD中的临床后果尚不明确,需建立有效风险获益比前解决关键研究目标。
研究设计与样本
- 综述,总结硬骨抑素阻断在CKD-MBD中的潜在效应并识别需解决的研究目标。
主要发现
- 硬骨抑素是骨形成和矿化的强效抑制剂,主要由骨细胞产生。
- 硬骨抑素单抗(如romosozumab)是治疗骨质疏松的有前景策略。
- 硬骨抑素单抗可能干扰CKD-MBD中甲状旁腺功能亢进、肾性骨营养不良和血管钙化的多重交互。
临床怎么用
- 在CKD-MBD患者中考虑硬骨抑素单抗治疗前,需评估其多系统交互风险,等待风险获益比建立。
局限性
- 硬骨抑素阻断在CKD-MBD中的临床后果尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Canonical Wnt signalling activity is a major player in physiological and adaptive bone metabolism. Wnt signalling is regulated by soluble inhibitors, with sclerostin being the most widely studied. Sclerostin's main origin is the osteocyte and its major function is blockade of osteoblast differentiation and function. Therefore, sclerostin is a potent inhibitor of bone formation and mineralization. Consequently, blocking sclerostin via human monoclonal antibodies (such as romosozumab) represents a promising perspective for the treatment of (postmenopausal) osteoporosis. However, sclerostin's physiology and the effects of sclerostin monoclonal antibody treatment are not limited to the skeleton. Specifically, the potential roles of sclerostin in chronic kidney disease (CKD) and associated pathologies covered by the term chronic kidney disease and mineral bone disorder (CKD-MBD), which also includes accelerated cardiovascular calcification, warrant specific attention. CKD-MBD is a complex disease condition in which sclerostin antibodies may interfere at different levels and influence the multiform interplay of hyperparathyroidism, renal osteodystrophy and vascular calcification, but the clinical sequelae remain obscure. The present review summarizes the potential effects of sclerostin blockade in CKD-MBD. We will address and summarize the urgent research targets that are being identified and that need to be addressed before a valid risk-benefit ratio can be established in the clinical setting of CKD.
引用
- Brandenburg VM, Verhulst A, Babler A, et al. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant. 2019. PMID: 29846712. doi:10.1093/ndt/gfy129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。